

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting

FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)

10903 New Hampshire Avenue, Silver Spring, Maryland

December 18, 2019

DRAFT QUESTIONS

1. **DISCUSSION:** Please discuss whether the evidence from Cohorts 5 and 6 of EZH-202 is sufficient to establish the benefit of tazemetostat in patients with epithelioid sarcoma.
2. **VOTE:** Does the demonstrated benefit of tazemetostat outweigh the risks of the drug in the proposed indication?

DRAFT